Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary
May 12, 2021
Earnings Call Speaker Segments
Oliver Maier
executiveGood afternoon, and thank you for being with us today. I'd like to welcome everyone to the First Quarter 2021 Conference Call. Joining me on the call today are Werner Baumann, our CEO, and Wolfgang Nickl, our CFO, and the businesses are represented by the responsible Management Board Members. For Pharmaceuticals, we have Stefan Oelrich. For Consumer Health, we have Heiko Schipper. For Crop Science, we have Liam Condon. To provide additional time for Q&A, we have streamlined the prepared remarks for today's call, and as usual, we posted our slides at the same time as we shared our release. Hopefully many of you had a chance to review them before the call. That being said, Werner will begin today's call as usual with an overview of the key developments in the first quarter. Wolfgang will then cover the performance of our businesses as well as the outlook for 2021 before we open up for the Q&A session. I'd like to start the call today by drawing your attention to the cautionary language that is included in our safe harbor statement as well as in all the materials that we have distributed today. With that, I hand it over to you, Werner.
Werner Baumann
executiveOkay, thank you, Oliver. Good afternoon, everyone. I'm glad to have you join this conference call. We're reflecting on a quarter where we engaged intensively with investors, and we truly value that dialogue and your contributions. At the JPMorgan conference and on our Capital Markets Day, we talked about how we're speeding up our strategy and laid out specific midterm targets. We shed more light on Pharma's LoE approach, the late-stage pipeline, and the new modalities we're putting money into. We also offered further detail on our midterm growth plans in Crop Science and on our emphasis on sustainable, profitable, above-market growth in Consumer Health. Our midterm targets are unambiguous, whether in innovation, sustainability or our financials. Before we turn to the quarterly financials, there are a few other matters I want to touch on briefly. On behalf of the whole Board of Management, I want to express our thanks for the strong backing and endorsement you showed during our annual shareholders meeting. We understand what you expect from us, and we are laser-focused on delivering. We're seeing strong momentum around a sustainability agenda that is now genuinely global and around the opening up of new technologies that matter greatly for tackling some of the world's biggest challenges.
Werner Baumann
executiveThe U.S. administration has only just put together its highly ambitious sustainability agenda. At the climate summit in April, we witnessed numerous countries commit to extensive decarbonization plans. Bayer is ready to take a leading role here. Innovation is hugely important in that respect. A study the European Commission commissioned has reached the conclusion that modern gene editing technologies — and, for that matter, traditional GMO as well — present no risk to mankind or the environment. Given our expertise and our considerable investments in new technologies across health and nutrition, we are very well positioned to capture the long-term innovation potential of the Bio Revolution. Having said that, we believe we will gain from these developments in the political and regulatory framework, for one simple reason. Our solutions make a significant contribution to addressing climate change. They also bring about better health and nutrition for people around the globe. Just consider our new carbon capture initiative, which we started in 2020, and we will scale it up quickly. We are one of the founding members of the newly established LEAF Coalition, which aims to protect tropical forests and sequester carbon. We truly have many good reasons to feel optimistic about the future. Before we move on, I would also like to offer a few comments on the glyphosate litigation.
Werner Baumann
executiveTalks are ongoing with plaintiffs' counsel as we work toward settlements covering the rest of the current cases. Roughly 96,000 claims across the Roundup litigation as a whole fall under settlement agreements already executed, are in process, or failed to satisfy eligibility criteria and were therefore disqualified. As for possible Roundup cases down the road, the preliminary approval hearing on the revised class settlement agreement is now scheduled for next week, on May 19th. Moving to quarterly performance, the year got off to a very strong start, particularly bearing in mind that we were up against an exceptionally robust prior-year quarter, which pandemic-driven early stocking across our businesses had boosted. In agriculture specifically, the market backdrop remains favorable, with corn and soybean futures prices still firm. That solid underlying performance, though, is obscured by considerable currency headwinds, in line with what our guidance anticipated. On our February full-year conference call, we noted that we anticipated adverse currency effects on sales of roughly EUR 1 billion in the first quarter by itself and EUR 2 billion across the full fiscal year, which of course hits earnings too. I'll close with a brief innovation update.
Werner Baumann
executiveWe’ve just announced that finerenone hit the primary endpoint in the phase III FIGARO-DKD cardiovascular outcome study involving patients who have chronic kidney disease along with type 2 diabetes. When added to standard of care, finerenone meaningfully lowered the combined risk of time to first occurrence of cardiovascular death or non-fatal cardiovascular events compared with placebo. That supports the fact that we are well along with our three late-stage pipeline assets: finerenone, Nubeqa, and Verquvo. We’ve taken considerable risk out of our pipeline and expect these assets to deliver substantial contributions to growth. In Crop Science, we’ve entered an exclusive collaboration with RAGT to jointly develop state-of-the-art wheat hybrids for the European market. This collaboration creates the opportunity to improve yields and robustness of wheat, the world’s most widely grown food crop. In Consumer Health, we keep investing in high-growth opportunities such as Care/of and new product launches. In Brazil, for instance, we recently introduced our new dry skin range for Bepanthen. Throughout the year, we’ll see additional launches of this new Bepanthen line extension and others that will contribute to our sales growth. Overall, we’re more positive on agriculture market sentiment, and if that holds, it should benefit our Crop Science business in 2021.
Werner Baumann
executiveOn the Pharma side, we anticipate that our growth momentum will pick up sequentially as the year unfolds. Naturally, we are getting ready for a successful launch of finerenone during the second half of the year, along with additional rollouts of Nubeqa and Verquvo. In Consumer Health, we are resolved to beat the market this year. With that, I'll hand things over to you, Wolfgang.
Wolfgang Nickl
executiveThank you, Werner. Ladies and gentlemen, a warm welcome from me as well. I'll now take you through how our business performed in the first quarter, and after that I'll cover the financial outlook for the fiscal year. In the first quarter of this year, sales rose 3% to EUR 12.3 billion on a currency- and portfolio-adjusted basis. EBITDA before special items declined 6% year-on-year, landing at EUR 4.1 billion, which corresponds to an adjusted EBITDA margin of 33.4%. As Werner pointed out, it's important to note that solid underlying momentum was obscured by considerable currency headwinds. To be specific, foreign exchange effects weighed on sales to the tune of EUR 938 million, while EBITDA before special items took a hit of EUR -337 million. Core earnings per share for the first quarter reached EUR 2.59, ahead of expectations. Underlying performance nearly offset negative currency headwinds amounting to EUR 0.22. The core financial result improved to EUR -385 million from EUR -493 million, driven mainly by currency effects and lower interest rates. Our core tax rate for the quarter was 24.3%, in line with last year. For the full year, we still expect it to come in around 23%, as previously guided. Earnings per share stood at EUR 2.13, primarily affected by the customary adjustment for acquisition-related amortization.
Wolfgang Nickl
executiveBut there was a positive effect on EBITDA from relevant special items of EUR 0.05, largely because of a patent dispute settlement involving Cipro. The bridge is shown in the appendix to our presentation. Free cash flow for the first quarter of 2021 was EUR -3.2 billion, versus EUR -793 million in 2020. That figure includes roughly EUR 2.2 billion in settlement payouts tied to litigation. On top of that, free cash flow this year was reduced by higher tax payments and by accounts receivable that came in above expectations because sales were stronger; we expect that to even out as the year goes on. Net financial debt rose to EUR 33.9 billion in the first quarter, driven mainly by the negative free cash flow I just described. Let me add some further detail on how our businesses performed. Crop Science delivered strong sales growth of 6% on a currency and portfolio adjusted basis, with record quarterly sales in herbicides and fungicides. Regionally, LATAM and Asia Pacific increased significantly on a currency and portfolio adjusted basis, at 26% and 29% respectively. Our soybean franchise posted currency and portfolio adjusted growth of 3%, with solid performance from our Xtend platform in a growing North America market.
Wolfgang Nickl
executiveThe strong upward path for our fungicide platform carried on, with sales up 22% on a currency- and portfolio-adjusted basis, driven mainly by increased prices and higher volumes of Fox Xpro in Latin America. Each of our herbicides, environmental science, and vegetable seed segments posted substantial business growth across every region, which produced double-digit currency- and portfolio-adjusted expansion. Within herbicides, gains came from both higher volumes and higher prices. Corn and seeds and traits sales matched the prior year level, since solid momentum in EMEA and LATAM was largely cancelled out by a corn licensing agreement in North America that is expiring. Turning to earnings, EBITDA before special items fell 6% to EUR 2.4 billion. Higher prices and contributions from existing efficiency programs were partly offset by the negative sales mix effect I mentioned from the North America license expiry and from losing the thiacloprid registration in EMEA. On top of that, EUR 252 million in sharply negative currency effects weighed on our earnings. Currency- and portfolio-adjusted sales for our Pharmaceuticals division were level with the prior year. Eylea and Xarelto, our two blockbuster drugs, both performed strongly, with Eylea sales up 16%. Xarelto posted 7% currency- and portfolio-adjusted growth against an exceptionally strong quarter in the prior year.
Wolfgang Nickl
executiveWhen it comes to elective treatments, we saw solid growth momentum in the first quarter for the IUD franchise, which grew 8%, and for our radiology business, which grew 3%. Conversely, sales of Avelox and Glucobay declined, which was tied to how the volume-based procurement policy has been implemented in China. Our hemophilia franchise was hit particularly hard by inventory buildup in the prior-year quarter as well as by competition. Growth from Jivi only partly offset the declines of Kogenate and Kovaltry. Competition in the U.S. had a negative impact on sales of Nexavar, our cancer drug, which fell 22% on a currency and portfolio adjusted basis. Turning to our bottom line, the negative price effects I mentioned, together with a negative currency effect of EUR 57 million, were only partly offset by cost containment and volume growth, and that produced a 6% decline in our EBITDA before special items. We'll finish the divisional updates with Consumer Health. Sales were down 4% on a currency and portfolio adjusted basis, coming after an exceptionally strong prior-year quarter with 14% CPA growth. This was combined with a weak flu season and continuing COVID-19 related lockdown measures. Lower demand for our cough and cold products drove a significant 30% decline in our allergy and cold category in the first quarter.
Wolfgang Nickl
executiveConversely, dermatology and nutritionals posted robust gains of 7% and 5%, respectively. That performance reflects sustained appetite for preventive health products. Across the board, we keep beating the Consumer Health market. At Consumer Health, our gain EBITDA margin rose 180 basis points, reaching 23.3%, helped by proceeds from divesting non-core brands and restrained marketing outlays amid a volatile market backdrop. Currency movements cost us EUR 26 million. Turning now to our full-year guidance. Obviously, 2021 got off to a really strong start with the first quarter, and we feel good about how business will develop this year. We are reaffirming the outlook we gave in February. Keep in mind that this guidance rests on constant currencies — that is, average actual 2020 exchange rates. The constant-currency outlook appears in the light blue column at the left of the chart. In the gray column at the right, we show the currency impact for fiscal year 2021 assuming currencies held at the 2020 year-end exchange rate as presented in February. One more point: the full-year currency impact would not differ substantially if we used the current exchange rates as of the end of April.
Wolfgang Nickl
executiveKeep in mind that because of how our business fluctuates with the seasons—particularly in Crop Science—and because the euro has strengthened considerably against the U.S. dollar compared with last year, the adverse currency effect falls more heavily in the first half of the year. Our guidance is based on our current business and does not incorporate any effect from the planned divestment of our environmental science business. I'd also like to point out a tool we're bringing out to help you even more when modeling how currency affects net sales at Bayer. We expect to make this currency simulation tool available to you next week. After that, we intend to refresh it on a quarterly basis. With that, Oliver, I'll turn the call back to you so you can begin the Q&A, please.
Oliver Maier
executiveThanks, Wolfgang. I appreciate the recap of the update. So without any further delay, let's go ahead and take questions from the line.
Operator
operatorLadies and gentlemen, we're moving into the question-and-answer portion now. To ask a question, just press star and then one on your phone's keypad. Should you want to withdraw your request, press star followed by two. Please hold a moment while we take the first question. Our first question is from the line of Mr. Andrews. Kindly give us your name and company name, then go ahead with your question.
Vincent Andrews
analystVincent Andrews here from Morgan Stanley. Morning, everyone. Liam, I wanted to ask whether you could update us on the U.S. soy market — volume, price — and I suppose what I really want to get a handle on as well is where you expect your XtendFlex acres to land this year. One of your competitors said in their results that the market has become a bit more competitive. I just want to hear how you see things at this point.
Liam Condon
executiveOkay, many thanks, Vincent. As we mentioned during the previous call, the U.S. soybean sector is extremely competitive at the moment. Our Q1 results actually came in above what we had expected internally. The XtendFlex approval arrived in time for us. We brought the XtendiMax system to market. In my view, the commercial team has simply done an excellent job getting this launched into the market. Broadly speaking, where pricing is concerned, we are roughly flat up to now. Our pricing lists went out prior to the commodity price run-up. The Xtend system is flat. We had XtendFlex. From a pricing standpoint in the market, we carry a modest premium. Overall, when it comes to competition, we are quite confident that we will be the number one system and will stay the number one system in soybeans this year. On acres, we don't know precisely how things will play out. At present, our internal estimate is roughly 89 million acres. That would be 6 million above last year. We'll be on at least 50% of those acres with the full Xtend system — Xtend perhaps two-thirds, XtendFlex perhaps one-third. I hope that gives you some sense of how we view the market.
Vincent Andrews
analystYes. Thanks a lot. As a quick follow-up, are you running into any problems with increased raw material costs in crop chemistry or with seed production expenses as we head into the LATAM season, or with freight more broadly?
Liam Condon
executiveYes, our costs are higher, but for the most part we had already built those into the forecast we started with. When we gave guidance for 2021, that guidance in fact assumed elevated expenses — freight, for instance, along with other procurement costs. There were a few costs we didn't anticipate. Take, for example, a Texas plant that was shut down for a week or two because of the freezing cold weather, and that created some idle costs. As for any costs that weren't planned, we would naturally look to offset them through efficiencies over the course of the year. Nothing stands out to me as a major worry at this point, given our planning and what we've managed to deliver so far in Q1.
Vincent Andrews
analystThank you very much.
Liam Condon
executiveSure.
Operator
operatorOur next question is from Mr. Verdult. Kindly give us your name and the company you represent, then go ahead with your question.
Peter Verdult
analystThank you, Peter Verdult from Citi. I have two questions, please. It feels a bit like Groundhog Day. They resemble what I asked back at Q4. The first is for Liam. I just want to understand better why crop guidance has not been increased given the Q1 trends, your remarks about an improving outlook, and likely seeds pricing power later this year, considering where commodity prices stand. Are there other factors you would want to highlight? Is this you taking a conservative stance? Could you give us some sense of the seeds pricing power you might expect later this year? Second, Stefan, on Pharma, what are the latest timelines for some of the important phase II assets you have, the P2X3 antagonist and the Factor XI program? Can you remind us what kind of data we would like to see this year? Just quickly, my usual one for you, Nubeqa and Vitrakvi. Can you give us a feel for whether we are getting any nearer to those two products entering the top 15 drug list at Bayer? Thank you.
Liam Condon
executiveYes. Thank you very much, Peter. I'll address the first question. Regarding guidance, is there anything we're worried about that we'd want to flag as the reason we haven't raised guidance yet? At a high level, I'd say no. Nothing stands out that would concern us unduly, nothing that hasn't been broadly consistent with what we expected up to now. Our honest view is that it's simply prudent given how early we are in the season at this point. We're in Q1. You really want to get through the Northern Hemisphere season, see how things actually unfold, see what sort of returns come through as well, and also get a read on what's happening with the pre-order book in LATAM, in the Southern Hemisphere season. We think it inherently makes far more sense, if you're going to revisit guidance, to do so at Q2 rather than already at Q1, because it's simply premature. We don't have sufficient data points to give any kind of number that would be solid and robust. If we're going to change anything, we'd rather give you a solid number.
Stefan Oelrich
executiveHey Pete, Stefan here. Regarding your question, on P2X3, we’re expecting a first phase II data readout in chronic cough later this year. That ought to give us a sense of the path ahead. On Factor XI, this year is going to be a busy one, since we anticipate multiple phase II readouts, so we should have some signal on the phase III direction we’re taking in the first half of next year.
Peter Verdult
analystAre Nubeqa and Vitrakvi close to breaking into the top 15?
Stefan Oelrich
executiveYeah, that’s a solid question. Nubeqa keeps delivering better than we expected. We ended the first quarter on a strong note, just as we did the prior year. As a small indication, I expect Nubeqa will rank among the top 15 by year-end.
Peter Verdult
analystAppreciate it.
Operator
operatorOur next question is from Mr. Jackson. Kindly give your name and the name of your company, and then go ahead with your question.
Joel Jackson
analystHello, good morning. Joel Jackson here from BMO Capital Markets. I appreciate you taking my questions. For my first question, regarding Brazil, could you discuss what the channel inventory level looks like in crop protection, and how you believe that might alter things?
Liam Condon
executiveSure, absolutely. Thanks, Joel — and by the way, I'm looking forward to seeing you next week. As for channel inventories in Brazil, right now we'd describe ours as very healthy. We've been seeing extremely robust demand, since acreage went up significantly, of course, both for the soybean season and now for the safrinha corn season. On the CP side, growth is very strong and in the double digits. At the moment it's actually too dry, so there are worries about harvest quality on the corn side. Essentially, this dryness means pest infestation is much higher, which essentially means we'll be selling more insecticides. That's simply going to be an outcome of the current situation. Usually, dryness isn't so good for fungicides. How much of the fungicides actually get used is the question. It's too early to call right now. We think our channel inventory level is very healthy. Overstocking doesn't concern me. Rather, we're trying to make sure we can keep the market supplied and meet the demand that's there.
Joel Jackson
analystThanks for that. My second question builds on something asked earlier. You had a solid, strong Q1. You mentioned how well Xtend did, and how the Xtend system performed in Q1, and soybean seeds came in better than you expected. For Crop Science, obviously, you've kept your full year outlook for sales and margins unchanged. On FX, you say it's roughly the same for you. Was some of that pulled forward into Q1? Are there offsets occurring later in the year that are balancing out your strong Q1 and keeping your guidance where it is? Maybe that's in soybean seeds or other areas of Crop Science. Could you help us understand some of those nuances? Thanks.
Liam Condon
executiveYes, absolutely. As I said to Peter a bit earlier, we don’t see anything at the moment that would throw us off track, nor anything unexpected on the horizon. We are still at a very early stage of the northern hemisphere season. In North America, corn planting may be about 70% done. Beans are 45% planted, yet corn has only 20% emerged and soybeans 10% emerged. The season remains quite young. A great deal can still change. We would prefer to wait at least until the northern hemisphere season wraps up in Q2. By then we will know how things have unfolded. We will know what type of returns were achieved, and we will know how much of Crop Protection products were actually applied given the weather conditions. We will know what pricing will look like for the fourth quarter and when the new North America season begins, and we will have an initial read on LATAM, especially Brazil, and then early orders for the southern hemisphere. With all of those factors at work, if we made any change to guidance at this point, whatever figure we provided would prove incorrect. We would rather provide a solid and robust outlook in Q2 instead of making any change now.
Joel Jackson
analystThanks.
Operator
operatorThe next question is from Mr. Faitz. Kindly give your name and your company's name, then ask your question.
Christian Faitz
analystYes, thank you. Good afternoon, everyone. I appreciate you taking my two questions. This is Christian Faitz from Kepler Cheuvreux. First, regarding Consumer Health: how do you expect sequential growth patterns to play out in allergy and cold across the consumer segments over the coming few quarters? Second, going back to agriculture production costs — Liam, I recall your comment that you're hedged for this year against rising crop prices, for which your production partners clearly expect compensation. Given that crop prices will most likely remain at significantly higher levels than in the last several years, have you already negotiated pricing for the next production season? Thanks.
Heiko Schipper
executiveAlright, so starting with Consumer and cough and cold in particular — clearly, that was a huge drag on the entire category throughout the industry in quarter one. Cough and cold is a quarter one business and to some degree also a quarter four one, since that's the period when most of the world hits its cold season. In Q1, the figures were down 50%-60% across markets, with some a bit worse than that. For Q4, I definitely don't expect another drop of that kind, because we're lapping numbers that were already lower. Q4 of last year was already declining. How positive it will be is just too early to say. We need to see how many people, especially in North America and Europe, will really stop wearing masks and get out again, but at least the comp is easier. We won't see another one of those brutal numbers like we had in Q1 that hit the whole industry.
Christian Faitz
analystAll right, thank you. Here's hoping folks will be hugging and kissing one another again before long.
Heiko Schipper
executiveEvery one of us would really like that to happen.
Liam Condon
executiveChristian, regarding that second point, you've got it right. The costs for our seed production are hedged. That hedging happens on a rolling basis, which explains why we aren't facing, say, an unexpected type of cost rise in this year, since it's hedged. Of course, even so, the actual costs will be considerably higher given the elevated commodity prices, and we keep hedging that as it rolls forward.
Christian Faitz
analystAll right, thank you. Appreciate it, Liam.
Operator
operatorMr. Jones has the next question. Kindly give your name and your company's name, and then ask your question.
Analyst
analystGood afternoon, everyone. I have a couple of questions too. First, regarding corn, a question for Liam. Growth in EMEA was offset by a decline in North America. Acres, I believe, are expected to be fairly flat, and one of your competitors has mentioned pricing up too. Does that mean you lost market share? Could you discuss the moving parts there? I wanted to ask about the seed price card for South America. Once again, a competitor is talking about pricing going up mid-single digits, and acres planted maybe 3% or 4% gains. Should that be how we think about it for Bayer Crop Science in H2? Thank you.
Liam Condon
executiveYes. Thank you, Tony. Regarding corn in North America, we mentioned during Q4 of last year that an older license is expiring, and that affects both the top and bottom line. If you take that effect out, our underlying business in North America would essentially be flat. We do expect corn to grow going forward. It will be among our growth drivers this year, but the corn license impact is there, and it will hit us particularly in Q1 and Q2. It's nothing to do with the underlying business — it's simply a license expiring that creates the effect. On seed prices in LATAM, specifically Brazil, we have already updated our price cards for corn, for the summer and safrinha season, and also for soybeans in the summer season. We're looking at what you could call high single digit, but it's actually low double-digit price increases. Just to give you a sense, those are price cards already published out there. Roughly 10%-ish is the price increase we're looking at.
Analyst
analystThanks — I really appreciate that.
Liam Condon
executiveAbsolutely.
Operator
operatorOur following question is from Mr. or Mrs. Engkilde. Kindly give your name and the company you represent, then go ahead with your question.
Laerke Engkilde
analystHello, everyone, and thank you for allowing me to ask. This is Laerke Engkilde calling from JPMorgan. First, regarding Crop Science, where we witnessed quite robust expansion this quarter, especially in herbicides and fungicides—you have already addressed some of that—how do you suggest we view whether this growth can be sustained, and was there any evidence of orders being pulled forward? Second, on Pharmaceuticals, would you expand on the impressive results for Eylea and indicate whether inventory building played any part? Last, if I may, considering your sizable U.S. footprint in Crop Science and the fact that Monsanto's IP is situated in the U.S., what should we anticipate concerning the possible effects of U.S. tax reform? Many thanks.
Liam Condon
executiveYeah. Many thanks. I’ll address the first one about whether growth is sustainable, and I suppose what’s really being asked is how much phasing plays into it. There’s definitely a certain amount of phasing effect here. We see it as fairly small, though it’s very difficult to pinpoint, since we think part of it is just tied to COVID and part is basically customers wanting to make sure they can get access, especially to crop protection products, in what you could call a lively market. On the whole, if these sales do involve a phasing effect, we’d expect it to be no more than a quarter, at most perhaps 20%, but it’s very hard to judge. That’s another reason we felt it was more prudent to revisit the overall guidance we provided rather than make any changes at Q2 right now.
Stefan Oelrich
executiveHello there. Regarding Eylea, that 16% figure is clearly something we feel very good about. I'd say it lines up quite well with everything we've been saying throughout last year amid COVID, when we were in fact growing share thanks to our strong data across 2020. We're seeing that carry into 2021, with share continuing to climb from what is already a very high level. There's no stocking involved in this. This reflects performance.
Wolfgang Nickl
executiveYeah, so regarding tax reform — naturally, any time taxes rise in a given place, that's going to show up in our models too. We still need to find out what the final specifics look like. For the near term, probably two things: first, because we carry a fairly large amount of deductions on the settlements, you shouldn't expect any effect on tax cash payments at any point soon — that's number one. Second, depending on the timing of when it comes out, you might see a modest adjustment to the deferred tax assets on our balance sheet; we'll need to look at the details there. We'll simply hold off until we've seen them, and after that we'll let you know what the impact is.
Laerke Engkilde
analystThanks.
Wolfgang Nickl
executiveThanks for joining us.
Operator
operatorOur next question is from Dominic Lunn. Please give your name and your company, and then ask your question.
Jo Walton
analystThis is actually Jo Walton calling from Credit Suisse on behalf of Dominic. I have a couple of questions, if you don't mind. First, regarding your Roundup settlement and the hearing scheduled for next week, could you share some sense of when you'd anticipate the judge issuing a ruling? Should we expect it soon after that hearing? What kind of timeframe would be reasonable to assume there? Second, near the start, you remarked that GM is now being viewed as a net positive with no downside. Are you seeing any of that acceptance coming from European politicians? Is there any possibility that GM or CRISPR, or the things that have proven so difficult for you to bring into Europe, might make their way into Europe or, more broadly, into Asia? Again, I'm sorry to return to the same topic of guidance. From what I understand about Germany, once you reach a point where you believe the market lacks the correct information, you're required to make a statement to us, and you don't have to wait for the quarter — and that has certainly occurred before. That implies to me you must still believe you're most likely to land in line with your guidance, in spite of all the positives we continue to hear about.
Jo Walton
analystI'm still a bit puzzled about which negatives might be restraining your outlook here. Just to remind us, we're aiming for roughly 2% growth at the top line for the year, and yet we've seen 6% in the first quarter. We've seen strong seeds and strong crop protection. Now you're saying the likelihood for seed pricing in the second half of the year is also very strong, with a pricing uplift. Please let me come back to what could go wrong and why you aren't more optimistic at this point. I'd also like, just on the Pharma side, for you to tell us whether there's anything off in the U.S. prescription trends that we can see, which don't show a massive uplift in Nubeqa. Have you simply done much better in terms of acceptance, for whatever reason, in the European markets, where you've initiated launch rather than in the U.S., or is the U.S. prescription data just not right and in fact you've got strong growth there as well? Thank you.
Werner Baumann
executiveOkay, thank you, Jo, for those questions. I’ll begin by addressing questions 1 and 3, and after that I’ll pass things to Liam. Liam will then hand over to Stefan for the final question. Let me begin with the hearing. The hearing regarding preliminary approval before Judge Vince Chhabria for our future settlements, which was submitted on February 3rd, is scheduled for the 19th. That’s almost precisely one week from today. Following that hearing, the judge will have roughly 30 days to review the settlement and issue his opinion. It could come in any form—you might get initial reactions and perspective even before the meeting, as we saw last time, during the settlement hearing, or at any point after that. Honestly, this is like peering into a crystal ball. We don’t know. We are well prepared. We have been extremely diligent, including in our negotiations with plaintiff counsel, in continuing to negotiate and address the points that were raised last year. We addressed those topics very diligently through the modified agreement that plaintiff counsel filed with our support. So let’s see—we are well prepared for whatever the outcome turns out to be, and we’ll proceed from there.
Werner Baumann
executiveRegarding guidance, I believe your question is about why an ad hoc approach might be necessary. As you would expect, whenever we close the books, our disclosure committee also reviews how the quarter qualifies, and that was carried out as part of the normal routine. We've gotten off to a solid start this quarter—there's no question about that. I think we've said several times now that, considering where we stand and the fact that a significantly important quarter still lies ahead, we would far prefer to tackle our guidance once we understand more about the year. That will rest on everything we know at this moment and on nothing unexpected occurring. Should all go as anticipated, we'll be well positioned to examine our guidance and then revise it as well following quarter two. Nothing else is behind it. I think you've rightly noted that market sentiment, commodity prices, and numerous other factors are very, very favorable. We hope that continues, and if it does continue or even improves, our guidance will capture that. I'll stop there. Naturally, the other businesses would also factor into that.
Werner Baumann
executiveHonestly, we're feeling pretty optimistic too. That said, I'll pass things over to Liam at this point.
Liam Condon
executiveYeah, Jo, regarding your question about gene editing in Europe — a publication from the European Commission really marked a milestone for Europe. From my own conversations with politicians at the European level, I can tell you there's broad political backing for legislation that would support bringing gene editing into European agriculture. The one caveat everybody raises is that they don't want this legislation to cover GMOs as well, since they believe that technology has been burned in Europe when it comes to consumer acceptance. When it comes to gene editing, there's common acceptance among political parties and personalities that this technology is needed to help feed a growing population sustainably. I think it's really a matter of getting the right legislation in place now. There is an absolute will and intent to do that. This won't just benefit Europe — it will particularly also benefit other parts of the world that look to Europe from a regulatory point of view. Take Africa, for example, and parts of Asia, which have been reluctant to embrace GMO technology: if Europe changes its legislation, they will become at least open to gene editing technology, which will for sure help advance agriculture in those geographies.
Stefan Oelrich
executiveRegarding your question about Nubeqa, Jo — as I mentioned at the start of this call, we're very happy with how things are going. I've repeated this point many times over the past year, and we also provided some indication of where we expect sales to end up. On your specific market research questions: it's possible that some of the access programs we ran early on have caused the secondary data to be somewhat disrupted or skewed. That could well be the case. Also, please keep in mind that for the time being, we hold a different set of indications compared with some of our direct competitors. That too will shift as time goes on, but for now, that's the situation. One of the major points that I think is still absent is that we're now, gradually but steadily, returning to the field for direct customer contact. More and more, our territories are moving back into a direct customer-facing mode. Our digital engagement with customers has been highly successful and has helped us drive uptake. Now that we're able to add face-to-face interaction across the board on top of that, we're quite optimistic. In Europe, we're seeing strong early signals.
Stefan Oelrich
executiveUp to now, the pricing and reimbursement landscape in Germany has worked in our favor, and that shows in the uptake, which keeps growing even following the AMNOG ruling and the price negotiation we went through for Nubeqa. So far, this is looking genuinely good.
Jo Walton
analystI appreciate that.
Operator
operatorMr. Zechmann, our next question is from your line. Kindly give us your name and your company, and then ask your question.
Gunther Zechmann
analystGood afternoon — Gunther Zechmann from Bernstein here. I've got a few questions for Liam, if I may. The first concerns input costs: a number of your competitors have said that prices for intermediates and active ingredients have gone up. Could you tell us what you're currently seeing in cost of goods sold, and what the outlook is for this year? Second, given the strong soft commodity price environment, what benefit do you see — and do you expect to see — in your precision agriculture business for the remainder of the year? Does that support pricing? I know historically you've discounted steeply there. Is that getting better, or are you pushing it to drive further volume adoption? What's your thinking on that? And the last one is on the glyphosate settlement. Of the 96,000 claims overall that either fall under the agreements or failed to meet the eligibility requirements, could you give us the split between those two categories, please?
Werner Baumann
executiveOkay, so Liam will kick things off, and after that I’ll take on the second question you raised, Gunther.
Liam Condon
executiveThanks a lot, Gunther. Regarding input costs, I touched on this a bit earlier — we had in fact budgeted for higher input costs this year, especially freight and logistics. Those costs are clearly materializing now. Supply is tight for a lot of raw materials, but it isn't much worse than what we planned for. If any cost goes beyond our plan, we would obviously just offset it through efficiency measures. Net, we don't expect extra input, freight, or logistics costs to hit our bottom line compared with what we've already forecast. On the commodity price benefits — and I know your question was specifically about digital — I think the single biggest thing, and it's always important to keep in mind, is that this run really only began once the price lists were published for North America in Q4 of last year. From a seed and trait standpoint, we've missed the season, the season that's ongoing. Where a new opportunity exists is, of course, as we move into the new season at the end of this year, and typically as much as 20% of our seeds might be sold in Q4.
Liam Condon
executiveThere is a chance here. Just what that chance looks like is something we'll be working out during Q2. And that's yet another factor behind our view that guidance ought to be held back, then revisited only in Q2, once additional data points are available. Certainly, an opportunity exists there. On the crop protection side, the opportunity is obvious, since farmers facing those elevated commodity prices will be motivated to safeguard their crops. The likelihood of applying greater amounts of fungicides and herbicides runs high, given that the relative payoff from doing so, compared with forfeiting part of the harvest, is extremely large. Upgrades could well materialize there. Once more, we'll only find out somewhat later in the season, after the crop has completely emerged. Those represent the largest opportunities. On the digital side, by contrast, market penetration is plainly our primary objective at present. This isn't a case where we're attempting to extract every last dollar from the system. It's a classic digital platform situation, in which the greatest penetration typically delivers the biggest long-term gains. That explains why I draw a distinction between what's achievable in seeds and trades and crop protection, and then on the digital side, in relation to the higher commodity prices.
Werner Baumann
executiveYeah. Thanks, Liam. Gunther, regarding your second question, we've included the cases that didn't qualify so you can see how many are off the table. You should assume that the count of cases that didn't qualify isn't that material in the grand scheme of things. Yeah. The key takeaway for you is that 96,000 have been resolved one way or the other.
Gunther Zechmann
analystAll right. That was quite useful. Thanks.
Werner Baumann
executiveThat's all good.
Operator
operatorOur next question is from Mr. Bray. Kindly give us your name and your company's name, then go ahead with your question.
Sebastian Bray
analystYes, hello, and good afternoon. This is Sebastian Bray from Berenberg Bank. I have a few questions, mainly about agriculture, please. The first concerns environmental sciences. That business has been growing rather well. Would I be correct that Bayer isn't selling off the entire unit? According to the report I read, just EUR 600 million of the EUR 1 billion — a bit more in sales — is being offered for sale. Where exactly will the remaining EUR 400 million and change be redirected? And what do those pieces consist of? My second question is about cotton. That's another commodity whose price has risen sharply of late. How is that portfolio doing on the seed side? The final one concerns glyphosate holdouts. Do we have any signal — I'm not sure how many holdouts there actually are, perhaps around 30,000 — an update would be appreciated, about whether push cases go to trial? What would be the earliest date on which that could occur? Thank you.
Werner Baumann
executiveOkay. I’ll take your final question first, and after that Liam will address your first one about the environmental science business — specifically how large the piece being sold is. He’ll also cover your point on cotton, given that pricing has stayed high and how that affects our seeds portfolio. On holdouts: yes, there are several holdouts. We’re in negotiations with every lawyer who represents plaintiffs, and in certain instances those are even attorneys handling just a small number of cases. Naturally, some have larger inventories. Our stance is that we keep our discipline consistent with the quality of the portfolios the plaintiff lawyers represent, and that discipline — plus being very direct with them about it — has in fact helped considerably, and we’ll remain on that course. Two cases could go to trial in July. Whether they actually do depends partly on — maybe some of them, there are 2, to be precise, that would come up in July. Whether perhaps one or the other gets settled, as we have done before, and/or the question of whether the courthouses are truly operational again by then for, say, larger multi-week trials.
Werner Baumann
executiveYeah. That's something we don't know. With that, over to Liam.
Liam Condon
executiveYeah. Thanks, Sebastian. So with Environmental Science, roughly two-thirds of that business is what we refer to as the classic Environmental Science — the professional side, the piece we intend to divest. About one-third is lawn and garden, which runs through Scotts as a distributor. The professional business is the only part being divested, and that explains the gap between the two, say, in how large each business is. Environmental Science got off to a really strong start this year, with growth of almost 10%. That comes from both Roundup, where demand is high, and vegetation management. All in all, I'd call it a very strong beginning to the year. On cotton this year, we expect acres to be more or less flat. It remains quite difficult to predict, but probably flattish acres in the U.S. We do expect to pick up market share, especially since we'll be launching our newest biotech trait, ThryvOn, which is highly effective at managing thrips and aphids — so, sucking pests of that kind. We clearly expand. Of course, we already hold a very strong leading market share position, but we expect to gain further share here. All in all, I think, again, considering where commodity prices stand, there's possibly an opportunity for somewhat more acreage to be planted than what we currently expect.
Liam Condon
executiveWe expect to see that in Q2.
Sebastian Bray
analystThat’s useful — thanks for answering my questions.
Operator
operatorSorry, Mr. Maier — no more questions right now. Go ahead with whatever else you'd like to add.
Oliver Maier
executiveGreat. Thanks a lot, Aman. Thank you, everyone, and thanks to all of you for spending your time and giving us your attention today. We really appreciate it. That brings today's call to an end, and we look forward to speaking with you all again before long. Many thanks. Goodbye.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.